display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positive
la/mBC - HER2 positive - 2nd Line (L2)
HER2 inhibitor
neratinib based treatment
neratinib ExteNET
neratinib plus capecitabine NALA NALA ...
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine HER2CLIMB ... HER2CLIMB

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons